Cargando…

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

BACKGROUND: The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies carried an increased risk of HIV infection after vaccination. Thus, understanding Ad seropositivity in humans is important to the development of an AIDS vaccine. Here, we analyze th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Cheng, Wang, LingShu, Gall, Jason G. D., Nason, Martha, Schwartz, Richard M., McElrath, M. Juliana, DeRosa, Steven C., Hural, John, Corey, Lawrence, Buchbinder, Susan P., Nabel, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319553/ https://www.ncbi.nlm.nih.gov/pubmed/22496775 http://dx.doi.org/10.1371/journal.pone.0033969

Ejemplares similares

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5
por: Toivonen, Raine, et al.
Publicado: (2012)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Use of adenovirus type-5 vectored vaccines: a cautionary tale
por: Buchbinder, Susan P, et al.
Publicado: (2020)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses
por: Bruder, Joseph T., et al.
Publicado: (2012)

Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells
por: Cheng, Cheng, et al.
Publicado: (2007)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Correction: Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses
por: Bruder, Joseph T., et al.
Publicado: (2012)

Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine
por: Schmidt, Katja G., et al.
Publicado: (2023)

A multiclade DNA/Ad vaccines for AIDS: the present and next generation
por: Nabel, Gary J
Publicado: (2006)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
por: Fitzpatrick, Zachary, et al.
Publicado: (2018)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

Adding unaligned sequences into an existing alignment using MAFFT and LAST
por: Katoh, Kazutaka, et al.
Publicado: (2012)

Adding Pluggable and Personalized Natural Control Capabilities to Existing Applications
por: Lamberti, Fabrizio, et al.
Publicado: (2015)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
por: Zahn, Roland, et al.
Publicado: (2012)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Spatio-Temporal History of HIV-1 CRF35_AD in Afghanistan and Iran
por: Eybpoosh, Sana, et al.
Publicado: (2016)

AD OK for 2K AD
Publicado: (1999)

Development of an Ad5H3 Chimera Using the “Antigen Capsid-Incorporation” Strategy for an Alternative Vaccination Approach
por: Gu, Linlin, et al.
Publicado: (2016)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Effects of Adding Neutralized Red Mud on the Hydration Properties of Cement Paste
por: Kang, Sukpyo, et al.
Publicado: (2020)

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
por: Zafar, Sadia, et al.
Publicado: (2020)

ad
por: Sefcik, Justine
Publicado: (2020)

Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions
por: Yang, Wei-Xiong, et al.
Publicado: (2016)

Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
por: Flickinger Jr, John C, et al.
Publicado: (2020)

LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)
por: Sobieszczyk, Magdalena, et al.
Publicado: (2021)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Winning grants step by step: the complete workbook for planning, developing, and writing successful proposals
por: O'Neal-McElrath, Tori, et al.
Publicado: (2013)

Ad hoc wireless networking
por: Xiuzhen Cheng, Xiuzhen, et al.
Publicado: (2003)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool
por: Liu, Yawu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i854rceg49215ia6e9onufbfv5